Valuation: Pharmaniaga

Market Cap 1.27B 311M 276M 259M 234M 443M 30.01B 446M 3.11B 1.21B 15.31B 1.17B 1.14B 49.22B P/E 2026 *
16.4x
P/E 2027 * 14.5x
Enterprise Value 1.27B 311M 276M 259M 234M 443M 30.01B 446M 3.11B 1.21B 15.31B 1.17B 1.14B 49.22B EV / Sales 2026 *
0.31x
EV / Sales 2027 * 0.3x
Free-Float
37.97%
Yield 2026 *
15.3%
Yield 2027 * 20.6%
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Member of Audit Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as A Member of Nomination and Remuneration Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces second Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 13 October 2026 CI
08-13 Pharmaniaga Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-17 Pharmaniaga Berhad Announces Redesignation of Dato' Dr Faridah Aryani Binti Md Yusof from Member of Risk Committee to Independent and Non Executive Chairman of Risk Committee, Effective 16 July 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Redesignation of Encik Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Director from Alternate Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Chairman of the Risk Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Member of the Nomination and Remuneration Committee, Effective July 1, 2026 CI
06-10 Pharmaniaga Completes 5:1 Share Consolidation MT
05-28 Pharmaniaga says government of Malaysia accepts unit's tender to supply insulin for 3 years RE
05-18 Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 03 July 2026 CI
1 day-2.51%
1 week-6.73%
Current month-6.73%
1 month-16.38%
3 months-24.22%
6 months-22.40%
Current year-31.93%
1 week 0.96
Extreme 0.965
1.05
1 month 0.96
Extreme 0.965
1.21
Current year 0.96
Extreme 0.965
1.7
1 year 0.96
Extreme 0.965
1.7
3 years 0.65
Extreme 0.65
2.35
5 years 0.65
Extreme 0.65
4.4
10 years 0.65
Extreme 0.65
7.25
Manager TitleAgeSince
Chief Executive Officer 53 31/08/2024
Director of Finance/CFO 59 31/05/2012
Chief Administrative Officer 53 30/09/2024
Director TitleAgeSince
Director/Board Member 74 19/07/2022
Director/Board Member 62 31/08/2025
Director/Board Member 53 29/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
27/03/26 Buy

Director

300,000 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-2.51%-6.73%-31.93%-53.81% 319M
+1.45%-2.29%+36.97%+104.79% 1,032B
+0.50%-4.78%+35.41%+61.62% 614B
+1.72%+1.29%+15.86%+79.90% 471B
+0.10%-4.92%+59.84%+36.64% 350B
+1.63%+2.35%+23.85%+42.44% 337B
+1.56%-0.28%+13.75%+35.73% 268B
+0.53%-1.60%-5.45%+11.31% 246B
+1.15%-4.97%+36.88%+50.52% 218B
+1.68%-4.66%+26.99%+92.98% 179B
Average +0.80%-3.66%+21.22%+46.21% 371.52B
Weighted average by Cap. +1.26%-3.18%+30.02%+67.48%

Financials

2026 *2027 *
Net sales 4.13B 1.01B 898M 840M 762M 1.44B 97.52B 1.45B 10.09B 3.93B 49.75B 3.8B 3.72B 160B 4.26B 1.04B 926M 866M 785M 1.48B 101B 1.49B 10.41B 4.05B 51.29B 3.92B 3.83B 165B
Net income 93.3M 22.84M 20.27M 18.97M 17.19M 32.47M 2.2B 32.71M 228M 88.62M 1.12B 85.72M 83.88M 3.61B 113M 27.65M 24.54M 22.97M 20.82M 39.32M 2.67B 39.6M 276M 107M 1.36B 104M 102M 4.37B
Net Debt - -
Projected Income Statement - Annual - Pharmaniaga
Logo Pharmaniaga
Pharmaniaga Berhad is an investment holding company engaged in the provision of management services to its subsidiaries. The Company’s segments include Manufacturing, Logistics and distribution, and Indonesia. The Manufacturing segment is engaged in manufacturing of pharmaceutical products in Malaysia. The Logistics and distribution segment includes distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Indonesia segment is engaged in manufacturing and distribution of pharmaceutical and medical products in Indonesia. Its product portfolio comprises oral solid dosages, liquid, cream and small volume injectables. It also manufactures general pharmaceuticals, including penicillin, cephalosporin and over-the-counter products. Its research and development capabilities include drug formulation and analytical development, process scale-up, clinical research and product localization.
Employees
3,502
Date Price Change Volume
07/10/26 MYR 0.9700 -2.51% 3,485,300
06/10/26 MYR 0.9950 -3.40% 2,697,800
05/10/26 MYR 1.030 +3.00% 3,281,400
02/10/26 MYR 1.000 -0.99% 2,016,900
01/10/26 MYR 1.010 -2.88% 1,124,000
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Pharmaniaga
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9950MYR
Average target price
1.530MYR
Spread / Average Target
+53.77%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Pharmaniaga
  1. Stock Market
  2. Stocks
  3. 7081 Stock